



REMARKS

1 Plain radiograph

- 1.1 Many primary lung cancers are initially detected on chest radiograph.
- 1.2 In certain instances, the chest radiograph alone is sufficient for staging, e.g. when an obvious metastatic bone lesion is detected or when large bulky contralateral mediastinal lymph nodes are present.
- 1.3 Chest X-ray (CXR) can be used to monitor treatment response if CT is not available.

2 CT

- 2.1 CT is the main imaging modality of choice for evaluating patients with bronchogenic carcinoma.
- 2.2 CT has limitations in staging since there are no morphologic criteria to distinguish between benign and malignant lymph nodes, with low sensitivity and specificity in detecting nodal metastasis.
- 2.3 CT should include the adrenal glands.
- 2.4 CT has limited value in detecting chest wall and mediastinal invasion.

3 Fluorodeoxyglucose (FDG) PET-CT

- 3.1 Whole body FDG PET-CT is the preferred imaging modality for staging of non-small cell lung cancer in patients who are planned to be treated with curative intent.
- 3.2 FDG PET-CT has better sensitivity and specificity than CT alone in identification of nodal metastases with an overall sensitivity of 80–90% and specificity of 85–95%.
- 3.3 FDG PET-CT detects ~24% occult extrathoracic metastases in patients who are initially planned to undergo curative resection.
- 3.4 It decreases the number of futile thoracotomy by an additional 21%.
- 3.5 FDG PET-CT is an excellent tool for monitoring of treatment response.

4 Bone scan

- 4.1 Bone scintigraphy has high sensitivity (93.3%) for detecting osseous metastases.
- 4.2 Routine bone scintigraphy is not warranted, and is only reserved for symptomatic patients or those with biochemical abnormalities.
- 4.3 If whole body FDG PET has already been performed, additional bone scintigraphy is not necessary in most circumstances.

5 MRI

- 5.1 MRI is particularly useful in determining certain parameters of unresectability for superior sulcus cancer such as invasion into vertebral body, spinal canal, neural foramina, subclavian artery or brachial plexus.
- 5.2 MRI is useful in assessing chest wall and mediastinal invasion.
- 5.3 Using Cine MRI during free breathing, presence of sliding between the tumor and mediastinum or chest wall has been shown to be diagnostic of lack of invasion; the converse however may not necessarily indicate invasion since adhesion from local inflammatory changes may also restrict tumour motion.

REFERENCES

1. Ravenel JG, Mohammed TH, Rosenzweig KE, et al. ACR Appropriateness Criteria® Non-invasive Clinical Staging of Bronchogenic Carcinoma. Available at <https://acsearch.acr.org/docs/69456/Narrative/>. American College of Radiology. Accessed 2017 June 6.
2. Patz EF. Imaging bronchogenic carcinoma. *Chest*. 2000; 117: 90S-95S.
3. Higashino T, Ohno Y, Takenaka D, Watanabe H, Nogami M, Ohnayashi C. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. *Eur J Radiol*. 2005; 56: 48-55.
4. Bruzzi JF, Komaki R, Walsh GL, Truong MT, Gladish GW, Monden RF, et al. Imaging of non-small cell lung cancer of the superior sulcus: part 2: Initial staging and assessment of resectability and therapeutic response. *Radiographics*. 2008; 28: 561-572.
5. National Institute for Health and Clinical Excellence (2011) Lung cancer: diagnosis and management. NICE guideline (CG121).
6. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardiothorac Surg*. 2014; 45: 787-798.
7. Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. *J Thorac Oncol*. 2011; 6: 1367-1372.
8. Macmanus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. *Int J Radiat Oncol Biol Phys*. 2001; 50: 287-293.
9. Spira A, Ettinger DS. Multidisciplinary Management of Lung Cancer. *N Engl J Med*. 2004; 350: 379-392.
10. vanTinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. *Lancet*. 2002; 359: 1388-1393.
11. Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. *Clin Cancer Res*. 2006; 12: 97-106.
12. Min JW, Um SW, Yim JJ, Yoo CG, Han SK, Shim YS, et al. The Role of Whole-Body FDG PET/CT, Tc 99m MDP Bone Scintigraphy, and Serum Alkaline Phosphatase in Detecting Bone Metastasis in Patients with Newly Diagnosed Lung Cancer. *J Korean Med Sci*. 2009; 24: 275-280.